Exercise decreases among people taking GLP-1 medication - FirstWord Pharma

A groundbreaking study presented at ENDO 2026 reveals a critical and unexpected side effect of GLP-1 medications: individuals taking these highly popular weight-loss drugs are significantly decreasing their physical activity levels. Utilizing real-world Fitbit data from the National Institutes of Health's All of Us Research Program, researchers found a measurable decline in daily step counts and moderate-to-vigorous physical activity, challenging the assumption that weight loss naturally leads to increased movement. This paradox presents a significant concern for long-term health outcomes, particularly the preservation of lean muscle mass. These findings arrive as GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound, manufactured by pharmaceutical giants Novo Nordisk and Eli Lilly, continue to transform obesity and Type 2 Diabetes management. The study, led by Dr. Sajana Maharjan, found that average daily step counts dropped by 560 steps (from 5,047 to 4,487) and MVPA minutes by 6 minutes (from 28 to 22) after starting the medication, with the steepest declines noted in men and those with musculoskeletal pain. This reduction in activity is particularly problematic because GLP-1 drugs, while effective for fat loss, also contribute to a loss of lean muscle mass, making consistent exercise essential to mitigate risks like sarcopenia and compromised metabolic health. Mechanisms contributing to reduced activity may include altered energy balance, direct modulation of the brain's dopamine reward system, and common side effects such as fatigue. The immediate imperative for healthcare providers and patients is to implement targeted interventions that prioritize physical activity, especially resistance training, alongside GLP-1 pharmacotherapy. Experts from the Endocrine Society and other institutions are stressing that exercise cannot be an optional afterthought, urging for structured counseling and strategies to counteract muscle loss and maintain overall strength and function. As the market for these drugs continues its meteoric rise, pharmaceutical companies and public health bodies face mounting pressure to integrate comprehensive lifestyle support into treatment protocols, ensuring that the promise of weight management doesn't inadvertently lead to a decline in vital physical health. The future of obesity care hinges on a synergistic approach that combines potent medication with robust behavioral support.